通过直接测序检测c-ABL外显子7缺失的剪接变体的补充结果对Curvo等人发表于《白血病研究》的《伊马替尼耐药患者中无c-ABL外显子7的复发性剪接变体》的评论 - Suppr | 超能文献

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].

作者信息

Cho Eun Hae, Kang Seong Ki, Kim So Young

出版信息

Leuk Res. 2009 Mar;33(3):505-6. doi: 10.1016/j.leukres.2008.08.024. Epub 2008 Oct 9.

DOI:10.1016/j.leukres.2008.08.024

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].通过直接测序检测c-ABL外显子7缺失的剪接变体的补充结果对Curvo等人发表于《白血病研究》的《伊马替尼耐药患者中无c-ABL外显子7的复发性剪接变体》的评论

Leuk Res. 2009 Mar;33(3):505-6. doi: 10.1016/j.leukres.2008.08.024. Epub 2008 Oct 9.

2

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.伊马替尼耐药患者中一种无c-ABL外显子7的复发性剪接变体。

Leuk Res. 2008 Mar;32(3):508-10. doi: 10.1016/j.leukres.2007.04.018. Epub 2007 Jun 13.

3

Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.一名慢性髓性白血病患者携带新型e8a2 BCR-ABL转录本变体，对甲磺酸伊马替尼耐药。

Acta Haematol. 2008;120(3):146-9. doi: 10.1159/000178145. Epub 2008 Nov 28.

4

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.双费城染色体：甲磺酸伊马替尼治疗慢性粒细胞白血病的一个耐药因素。

Int J Lab Hematol. 2008 Aug;30(4):346-8. doi: 10.1111/j.1751-553X.2007.00957.x.

5

Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.伊马替尼耐药的慢性粒细胞白血病细胞对TRAIL诱导的凋亡的敏感性是通过下调Bcr-Abl以及c-FLIP来介导的。

Biochem J. 2009 Apr 28;420(1):73-81. doi: 10.1042/BJ20082131.

6

Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.伊马替尼耐药的人BCR-ABL阳性细胞中葡萄糖摄取和代谢异常。

Clin Cancer Res. 2009 May 15;15(10):3442-50. doi: 10.1158/1078-0432.CCR-08-3291. Epub 2009 Apr 28.

7

Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.伴有e6a2 BCR-ABL且对伊马替尼无反应的慢性粒细胞白血病：两例病例报告

Acta Haematol. 2009;122(1):11-6. doi: 10.1159/000230037. Epub 2009 Jul 29.

8

Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.BCR-ABL在K562慢性髓系白血病细胞中对Skp2的转录激活作用。

Leuk Res. 2009 Nov;33(11):1520-4. doi: 10.1016/j.leukres.2009.03.007. Epub 2009 Mar 28.

9

Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.慢性髓性白血病患者中BCR-ABL转录本过表达及伊马替尼耐药性的特异性评估

Eur J Haematol. 2009 Apr;82(4):292-300. doi: 10.1111/j.1600-0609.2008.01199.x. Epub 2008 Dec 17.

10

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.索拉非尼通过抑制其激酶活性以激活内源性线粒体途径，从而特异性地诱导表达BCR/ABL的细胞发生凋亡。

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

引用本文的文献

1

Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.通过长片段新一代测序技术快速鉴定费城阳性白血病患者的复合突变。

Eur J Cancer. 2014 Mar;50(4):793-800. doi: 10.1016/j.ejca.2013.11.030. Epub 2013 Dec 20.

2

Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.通过分子遗传和生物信息学方法对 ABL 外显子 7 缺失进行的特征分析并未显示其与慢性髓性白血病伊马替尼耐药有关。

Med Oncol. 2012 Sep;29(3):2136-42. doi: 10.1007/s12032-011-0092-9. Epub 2011 Oct 30.